Hybrigenics has developed an extended network of partnerships with pharmaceutical and biotechnology companies as well as prestigious academic institutes:

Servier, France.

Drug target discovery alliance in cancer.

National Cancer Institute, USA.

Collaboration in small molecule drug screening (in vitro and in vivo).

Boston Biochem, USA.

Collaboration in developing advanced ubiquitin-specific proteases biochemical assays.

Prestwick Chemical, France.

Collaboration in medicinal chemistry and protease-directed drug discovery.

Halle University, Germany.

Collaboration in molecular modelling and virtual screening.

Structural Genomic Consortium, Canada.

Collaboration in 3D structural studies.

Columbia University, USA.

Investigation of the ubiquitin/proteasome pathway.

University of Liverpool, UK.

Investigation of ubiquitin-specific proteases functions.

Institut Pasteur, Paris - France.

R&D agreements with leading scientific teams working at the prestigious Institut Pasteur.

Institut Curie, Paris - France.

Collaboration with the Institut Curie to study the functional proteomics of cellular development, signalling and carcinogenesis.

Nikem Research, Italy.

Collaboration in medicinal chemistry and protease-directed drug discovery.

Institut Cochin, Paris - France.

Collaboration with leading scientific teams on the ubiquitin/proteasome pathway and cell signaling.

Assistance Publique Hôpitaux de Paris, France.

Collaboration with clinicians on ubiquitin-specific proteases in cancer.